{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:52Z","timestamp":1763534332541,"version":"build-2065373602"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["2K12CA090628\u201321"],"award-info":[{"award-number":["2K12CA090628\u201321"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.blre.2023.101071","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T21:27:29Z","timestamp":1677792449000},"page":"101071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?"],"prefix":"10.1016","volume":"60","author":[{"given":"Sharina C.","family":"Macapagal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Nora","family":"Bennani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2023.101071_bb0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11899-016-0353-y","article-title":"T-cell lymphoma epidemiology: the known and unknown","volume":"11","author":"Phan","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"25","key":"10.1016\/j.blre.2023.101071_bb0010","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101071_bb0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0020","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.blre.2023.101071_bb0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11864-021-00873-w","article-title":"How to sequence therapies in peripheral T cell lymphoma","volume":"22","author":"Wudhikarn","year":"2021","journal-title":"Curr Treat Options in Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101071_bb0030","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.26270","article-title":"Aggressive T-cell lymphomas: 2021 updates on diagnosis, risk stratification and management","volume":"96","author":"Zain","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.blre.2023.101071_bb0040","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","article-title":"Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers","volume":"5","author":"Rodriguez","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"10.1016\/j.blre.2023.101071_bb0050","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101071_bb0060","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101071_bb0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2023.101071_bb0070","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101071_bb0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11912-020-00902-1","article-title":"Therapy of peripheral T cell lymphoma: focus on nodal subtypes","volume":"22","author":"Allen","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2559.2010.03704.x","article-title":"Pathology and biology of peripheral T-cell lymphomas","volume":"58","author":"de Leval","year":"2011","journal-title":"Histopathology."},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0085","first-page":"47","article-title":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/modpathol.3880289","article-title":"Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology","volume":"14","author":"Jaffe","year":"2001","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminhematol.2013.11.003","article-title":"Pathology of peripheral T-cell lymphomas: where do we stand?","volume":"51","author":"Gaulard","year":"2014","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101071_bb0100","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hon.3074","article-title":"Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: report from the prospective international T-cell lymphoma project","volume":"40","author":"Chiattone","year":"2022","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0105","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/bloodadvances.2020001581","article-title":"ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the international T-cell project","volume":"5","author":"Shustov","year":"2021","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.blre.2023.101071_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184667","article-title":"ALK-negative anaplastic large cell lymphoma: current concepts and molecular pathogenesis of a heterogeneous Group of Large T-cell lymphomas","volume":"13","author":"Pina-Oviedo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.blre.2023.101071_bb0115","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101071_bb0120","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101071_bb0125","series-title":"64th ASH annual meeting and exposition; 12\/11\/2022; New Orleans, Louisiana","article-title":"Long-term follow-up of clinical outcome determinants and correlative biological features from the Nordic NLG-T-01 trial","author":"Relander","year":"2022"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0130","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/PAS.0000000000001708","article-title":"JAK2 rearrangements are a recurrent alteration in CD30+ systemic T-cell lymphomas with anaplastic morphology","volume":"45","author":"Fitzpatrick","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41375-021-01321-2","article-title":"High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)","volume":"36","author":"Pritchett","year":"2022","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101071_bb0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-319-99716-2_3","article-title":"Tumor microenvironment in T-cell lymphomas","volume":"176","author":"Bennani","year":"2019","journal-title":"Cancer Treat Res"},{"issue":"11","key":"10.1016\/j.blre.2023.101071_bb0150","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2020.262659","article-title":"<i>CDKN2A<\/i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)","volume":"106","author":"Maura","year":"2021","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.blre.2023.101071_bb0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.blre.2023.101071_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.blre.2023.101071_bb0165","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0170","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101071_bb0175","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0180","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/path.5376","article-title":"Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell","volume":"250","author":"Yao","year":"2020","journal-title":"J Pathol"},{"issue":"25","key":"10.1016\/j.blre.2023.101071_bb0185","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0190","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.blre.2023.101071_bb0195","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.blre.2023.101071_bb0200","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101071_bb0205","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.blre.2023.101071_bb0215","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2023.101071_bb0220","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood."},{"issue":"15","key":"10.1016\/j.blre.2023.101071_bb0225","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0230","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenetics"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/17474086.2019.1583102","article-title":"New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination","volume":"12","author":"Ma","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101071_bb0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3233\/CBM-220013","article-title":"TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients","volume":"35","author":"de Padua Covas Lage","year":"2022","journal-title":"Cancer Biomark"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0245","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.16428","article-title":"The new biology of PTCL-NOS and AITL: current status and future clinical impact","volume":"189","author":"Timmins","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101071_bb0250","first-page":"859","article-title":"The discovery and development of romidepsin for the treatment of T-cell lymphoma","volume":"12","author":"Smolewski","year":"2017","journal-title":"Expert Opin Drug Discovery"},{"issue":"19","key":"10.1016\/j.blre.2023.101071_bb0255","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2023.101071_bb0260","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12185-017-2286-1","article-title":"Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study","volume":"106","author":"Maruyama","year":"2017","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0265","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101071_bb0270","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101071_bb0275","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.blre.2023.101071_bb0280","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101071_bb0285","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral Azacytidine in patients with relapsed\/refractory Angioimmunoblastic T-cell lymphoma: final analysis of the Oracle phase III study","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101071_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2022.07.009","article-title":"Real-world efficacy of 5-Azacytidine as salvage chemotherapy for Angioimmunoblastic T-cell lymphoma","volume":"22","author":"Yoon","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.blre.2023.101071_bb0295","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/13543784.2019.1667331","article-title":"Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"28","author":"Daher-Reyes","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.blre.2023.101071_bb0300","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41375-022-01571-8","article-title":"Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma","volume":"36","author":"Wong","year":"2022","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.blre.2023.101071_bb0305","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101071_bb0310","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1080\/10428194.2020.1765232","article-title":"Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis","volume":"61","author":"Zhu","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0315","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/1871520622666220610151603","article-title":"Pralatrexate for peripheral T-cell lymphoma (PTCL): chance only supports the prepared mind","volume":"23","author":"Altinay","year":"2022","journal-title":"Systematic review. Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.blre.2023.101071_bb0320","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2018-99-119684","article-title":"Management of Mucositis with the use of Leucovorin as adjunct to Pralatrexate in treatment of peripheral T-cell lymphomas (PTCL) \u2014 results from a prospective multicenter phase 2 clinical trial","volume":"132","author":"Shustov","year":"2018","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101071_bb0325","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/14712598.2012.670216","article-title":"Brentuximab vedotin in systemic T-cell lymphoma","volume":"12","author":"Oki","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"18","key":"10.1016\/j.blre.2023.101071_bb0330","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10168","key":"10.1016\/j.blre.2023.101071_bb0335","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0340","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12185-022-03469-8","article-title":"Dual inhibition of EZH1\/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1","volume":"117","author":"Ito","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2023.101071_bb0345","article-title":"An open-label, single-arm, phase 2 trial of Valemetostat in relapsed or refractory adult T-cell leukemia\/lymphoma","author":"Izutsu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101071_bb0350","first-page":"2553","article-title":"A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R\/R) Peripheral T-Cell Lymphoma (PTCL), Including R\/R Adult T-Cell Leukemia\/Lymphoma (ATL) - Valentine-PTCL01","volume":"138","author":"Francine","year":"2021","journal-title":"Blood."},{"issue":"S2","key":"10.1016\/j.blre.2023.101071_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/hon.14_2879","article-title":"First-in-human study of the EZH1 and Ezh2 dual inhibitor Valemetostat Tosylate (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphomas","volume":"39","author":"Ishitsuka","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101071_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.blre.2023.101071_bb0365","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101071_bb0370","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2021-148939","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 Primo trial: results of an interim analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood."},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101071_bb0375","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2021.39.15_suppl.7531","article-title":"A phase Ib study of a PI3K\u03b4 inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"39","author":"Jin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101071_bb0380","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2002.09.116","article-title":"Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer","volume":"20","author":"Crul","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101071_bb0385","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/0008-5472.CAN-16-0938","article-title":"The RAS-effector interaction as a drug target","volume":"77","author":"Keeton","year":"2017","journal-title":"Cancer Res"},{"issue":"286","key":"10.1016\/j.blre.2023.101071_bb0390","doi-asserted-by":"crossref","first-page":"ra65","DOI":"10.1126\/scisignal.2004018","article-title":"The chemokine CXCL12 generates costimulatory signals in T cells to enhance phosphorylation and clustering of the adaptor protein SLP-76","volume":"6","author":"Smith","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.blre.2023.101071_bb0395","first-page":"3957","article-title":"The CXCL12\/CXCR4 pathway as a potential target of Tipifarnib in acute myeloid leukemia and myelodysplastic syndromes","volume":"130","author":"Gualberto","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101071_bb0400","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2019-128513","article-title":"Proof of concept for Tipifarnib in relapsed or refractory Angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL): preliminary results from an open-label, phase 2 study","volume":"134","author":"Witzig","year":"2019","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2023.101071_bb0405","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","article-title":"Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas","volume":"118","author":"Witzig","year":"2011","journal-title":"Blood."},{"issue":"S2","key":"10.1016\/j.blre.2023.101071_bb0410","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/hon.2438_115","article-title":"Preliminary results from an open-label, phase II study of Tipifarnib in relapsed or refractory peripheral T-cell lymphoma","volume":"35","author":"Witzig","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101071_bb0415","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2021-147279","article-title":"Final results from a phase 2 study of Tipifarnib in subjects with relapsed or refractory peripheral T-cell lymphoma","volume":"138","author":"Witzig","year":"2021","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0420","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.14984","article-title":"Mutations in the JAK\/STAT pathway genes and activation of the pathway, a relevant finding in nodal peripheral T-cell lymphoma","volume":"183","author":"Manso","year":"2018","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.blre.2023.101071_bb0425","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101071_bb0430","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.blre.2023.101071_bb0435","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.blre.2023.101071_bb0440","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood."},{"issue":"S2","key":"10.1016\/j.blre.2023.101071_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/hon.56_2879","article-title":"The combination of Duvelisib and Romidepsin (DR) is highly active against relapsed\/refractory peripheral T-cell lymphoma with low rates of Transaminitis: final results","volume":"39","author":"Horwitz","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0450","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101071_bb0455","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101071_bb0460","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V130.Suppl_1.818.818","article-title":"Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma (PTCL): a phase 1 dose-escalation study","volume":"130","author":"Shustov","year":"2017","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101071_bb0465","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2021-145495","article-title":"High rates of remission with the initial treatment of Oral Azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL): clinical outcomes and biomarker analysis of a multi-center phase II study","volume":"138","author":"Ruan","year":"2021","journal-title":"Blood."},{"year":"2022","series-title":"Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas. ASCO 22; 06\/02\/200; Chicago, Illinois","author":"Ruan","key":"10.1016\/j.blre.2023.101071_bb0470"},{"issue":"5","key":"10.1016\/j.blre.2023.101071_bb0475","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(15)70103-8","article-title":"Programmed cell death-1 inhibition in lymphoma","volume":"16","author":"Hawkes","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0480","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7150\/jca.17144","article-title":"Nivolumab as programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in tumor","volume":"8","author":"Guo","year":"2017","journal-title":"J Cancer"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0485","first-page":"64","article-title":"Neoplasms of follicular helper T-cells: an insight into the pathobiology","volume":"12","author":"Jain","year":"2022","journal-title":"Am J Blood Res"},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0490","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0495","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.blre.2023.101071_bb0500","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.blre.2023.101071_bb0505","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor Pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"10.1016\/j.blre.2023.101071_bb0510","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRPalpha requires fc-FcgammaR interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101071_bb0515","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0520","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0525","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101071_bb0530","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101071_bb0535","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.ijp_531_20","article-title":"Chimeric antigen receptor T cell: a cancer immunotherapy","volume":"54","author":"Singh","year":"2022","journal-title":"Indian J Pharm"},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0540","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1471-4906(03)00164-9","article-title":"Fratricide: a mechanism for T memory-cell homeostasis","volume":"24","author":"Callard","year":"2003","journal-title":"Trends Immunol"},{"key":"10.1016\/j.blre.2023.101071_bb0545","series-title":"Atlas of differential diagnosis in neoplastic","first-page":"21","author":"Bone","year":"2014"},{"issue":"30","key":"10.1016\/j.blre.2023.101071_bb0550","first-page":"3340","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human","volume":"39","author":"Pan","year":"2021","journal-title":"Phase I Trial J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101071_bb0555","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2021-149999","article-title":"A single-arm, open-label, pilot trial of autologous CD7-CAR-T cells for CD7 positive relapsed and refractory T-lymphoblastic leukemia\/lymphoma","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0560","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101071_bb0565","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V82.2.343.343","article-title":"Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia","volume":"82","author":"Pui","year":"1993","journal-title":"Blood."},{"year":"2020","series-title":"CD5 CAR T-cells for treatment of patients with relapsed\/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity","author":"Hill","key":"10.1016\/j.blre.2023.101071_bb0570"},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101071_bb0575","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1200\/JCO.2022.40.16_suppl.7028","article-title":"Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"40","author":"Pan","year":"2022","journal-title":"J Clin Oncol"},{"year":"2022","series-title":"The Cobalt-LYM Study of Ctx130: A Phase 1 Dose Escalation Study of CD70-Targeted Allogeneic Crispr-Cas9\u2013Engineered CAR-T Cells In Patients With Relapsed\/Refractory (R\/R) T-Cell Malignancies. European Hematology Associated 2022; Vienna","author":"Sharma","key":"10.1016\/j.blre.2023.101071_bb0580"},{"issue":"12","key":"10.1016\/j.blre.2023.101071_bb0585","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"year":"2022","series-title":"First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma. 64th ASH annual meeting and exposition; New Orleans, Louisiana","author":"Cwynarski","key":"10.1016\/j.blre.2023.101071_bb0590"},{"issue":"7","key":"10.1016\/j.blre.2023.101071_bb0595","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"25","key":"10.1016\/j.blre.2023.101071_bb0600","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101071_bb0605","first-page":"JCO2200343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of Talimogene Laherparepvec combined with Pembrolizumab for advanced melanoma","author":"Chesney","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101071_bb0610","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101071_bb0615","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.blre.2023.101071_bb0620","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.blre.2023.101071_bb0625","first-page":"3268","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.blre.2023.101071_bb0630","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:50Z","timestamp":1759437110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":126,"alternative-id":["S0268960X23000322"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101071","relation":{},"ISSN":["0268-960X"],"issn-type":[{"type":"print","value":"0268-960X"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101071"}}